71. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. (18th July 2019) Authors: Reich, K.; Warren, R.B.; Iversen, L.; Puig, L.; Pau‐Charles, I.; Igarashi, A.; Ohtsuki, M.; Falqués, M.; Harmut, M.; Rozzo, S.; Lebwohl, M.G.; Cantrell, W.; Blauvelt, A.; Thaçi, D. Journal: British journal of dermatology Issue: Volume 182:Number 3(2020) Page Start: 605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
72. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. (1st March 2020) Authors: Reich, K.; Warren, R.B.; Iversen, L.; Puig, L.; Pau‐Charles, I.; Igarashi, A.; Ohtsuki, M.; Falqués, M.; Harmut, M.; Rozzo, S.; Lebwohl, M.G.; Cantrell, W.; Blauvelt, A.; Thaçi, D. Journal: British journal of dermatology Issue: Volume 182:Number 3(2020) Page Start: 605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
73. Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2). (1st April 2021) Authors: Gordon, K.B.; Warren, R.B.; Gottlieb, A.B.; Blauvelt, A.; Thaçi, D.; Leonardi, C.; Poulin, Y.; Boehnlein, M.; Brock, F.; Ecoffet, C.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 4(2021) Page Start: 652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
74. Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2). (9th September 2020) Authors: Gordon, K.B.; Warren, R.B.; Gottlieb, A.B.; Blauvelt, A.; Thaçi, D.; Leonardi, C.; Poulin, Y.; Boehnlein, M.; Brock, F.; Ecoffet, C.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 4(2021) Page Start: 652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
75. Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. (1st April 2021) Authors: Blauvelt, A.; Paul, C.; van de Kerkhof, P.; Warren, R.B.; Gottlieb, A.B.; Langley, R.G.; Brock, F.; Arendt, C.; Boehnlein, M.; Lebwohl, M.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 4(2021) Page Start: 640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
76. Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. (6th September 2020) Authors: Blauvelt, A.; Paul, C.; van de Kerkhof, P.; Warren, R.B.; Gottlieb, A.B.; Langley, R.G.; Brock, F.; Arendt, C.; Boehnlein, M.; Lebwohl, M.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 4(2021) Page Start: 640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
77. Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis. (1st March 2022) Authors: Gordon, K.B.; Lebwohl, M.; Papp, K.A.; Bachelez, H.; Wu, J.J.; Langley, R.G.; Blauvelt, A.; Kaplan, B.; Shah, M.; Zhao, Y.; Sinvhal, R.; Reich, K. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
78. Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis. (24th November 2021) Authors: Gordon, K.B.; Lebwohl, M.; Papp, K.A.; Bachelez, H.; Wu, J.J.; Langley, R.G.; Blauvelt, A.; Kaplan, B.; Shah, M.; Zhao, Y.; Sinvhal, R.; Reich, K. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
79. Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. (10th April 2018) Authors: Papp, K.A.; Blauvelt, A.; Kimball, A.B.; Han, C.; Randazzo, B.; Wasfi, Y.; Shen, Y.‐K.; Li, S.; Griffiths, C.E.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 9(2018) Page Start: 1515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
80. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. (15th July 2018) Authors: Blauvelt, A.; Lacour, J.‐P.; Fowler, J.F.; Weinberg, J.M.; Gospodinov, D.; Schuck, E.; Jauch‐Lembach, J.; Balfour, A.; Leonardi, C.L. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗